Reference:
- Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381:
320-332.
- Stavropoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid: a
review of the literature. J Eur Acad Dermatol Venereol 2014;
28: 1133-1140.
- Pasmatzi E, Monastirli A, Habeos J, Georgiou S, Tsambaos D. Dipeptidyl
peptidase-4 inhibitors cause bullous pemphigoid in diabetic patients:
report of two cases. Diabetes Care 2011; 34: e133.
- Skandalis K, Spirova M, Gaitanis G, Tsartsarakis A, Bassukas ID.
Drug-induced bullous pemphigoid in diabetes mellitus patients
receiving dipeptidyl peptidase-IV inhibitors plus metformin. J
Eur Acad Dermatol Venereol 2012; 26: 249-253
- Attaway A, Mersfelder TL, Vaishnav S, Baker JK. Bullous pemphigoid
associated with dipeptidyl peptidase IV inhibitors. A case report and
review of literature. J Dermatol Case Rep 2014; 8: 24-28.
- García M, Aranburu MA, Palacios-Zabalza I, Lertxundi U, Aguirre C.
Dipeptidyl peptidase-IV inhibitors induced bullous pemphigoid: a case
report and analysis of cases reported in the European
pharmacovigilance database. J Clin Pharm Ther 2016; 41:
368-370.
- Béné J, Moulis G, Bennani I, et.al. French Association of
Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl
peptidase IV inhibitors: a case-noncase study in the French
Pharmacovigilance Database. Br J Dermatol 2016; 175: 296-301.
- Benzaquen M, Borradori L, Berbis P, et.al. Dipeptidyl peptidase
IV inhibitors, a risk factor for bullous pemphigoid: Retrospective
multicenter case-control study from France and Switzerland. J Am
Acad Dermatol 2018; 78: 1090-1096.
- Kridin K, Bergman R. Association of bullous pemphigoid with
dipeptidyl-peptidase 4 inhibitors in patients with diabetes:
estimating the risk of the new agents and characterizing the patients.JAMA Dermatol 2018; 154: 1152-1158.
- Varpuluoma O, Försti AK, Jokelainen J, et.al. Vildagliptin
Significantly Increases the Risk of Bullous Pemphigoid: A Finnish
Nationwide Registry Study. J Invest Dermatol 2018; 138:
1659-1661.
- Izumi K, Nishie W, Mai Y, et.al. Autoantibody Profile
Differentiates between Inflammatory and Noninflammatory Bullous
Pemphigoid. J Invest Dermatol 2016; 136: 2201-2210.
- Patsatsi A, Kyriakou A, Meltzanidou P, et.al. Βullous
pemphigoid in patients with DPP-4 inhibitors at the onset of disease:
does this differ from common bullous pemphigoid? Eur J Dermatol2018; 28: 711-713.
- Lindgren O, Varpuluoma O, Tuusa J, et.al. Gliptin-associated
Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26
in Bullous Pemphigoid. Acta Derm Venereol Mar 2019; doi:
10.2340/00015555-3166. [Epub ahead of print]
- Kasperkiewicz M, Zillikens D The pathophysiology of bullous
pemphigoid. Clin Rev Allergy Immunol 2007; 33: 67-77.
- Ujiie H, Muramatsu K, Mushiroda T, et.al. HLA-DQB1*03:01 as a
Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by
DPP-4 Inhibitors. J Invest Dermatol 2018; 138: 1201-1204.
- Aso Y, Fukushima M, Sagara M, et.al. (2015) Sitagliptin, a
DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in
patients with type 2 diabetes. Diabetes Res Clin Pract 110:
250-256.
- Sakaguchi S, Yamaguchi T, Nomura T, Ono M. (2008) Regulatory T cells
and immune tolerance. Cell 133: 775-787.
- Muramatsu K, Ujiie H, Kobayashi I, et.al. (2018) Regulatory
T-cell dysfunction induces autoantibodies to bullous pemphigoid
antigens in mice and human subjects. J Allergy Clin Immunol142: 1818-1830.
- Forssmann U, Stoetzer C, Stephan M, et.al. (2008) Inhibition of
CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated
recruitment of eosinophils in vivo. J Immunol 181: 1120-1127.